+关注
Dowi
暂无个人介绍
IP属地：陕西
1
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Dowi
10-10
👍🏻
辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率
Dowi
09-30
$特斯拉(TSLA)$
Dowi
09-28
$台积电(TSM)$
还能涨点不，亏了3个点了
Dowi
09-17
$英特尔(INTC)$
Dowi
09-17
$英特尔(INTC)$
Dowi
09-05
$英伟达(NVDA)$
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4187758296730972","uuid":"4187758296730972","gmtCreate":1724657821351,"gmtModify":1725499325512,"name":"Dowi","pinyin":"dowi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.07","exceedPercentage":"60.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.05","exceedPercentage":"60.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":1,"location":"陕西","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":358500956209384,"gmtCreate":1728564937981,"gmtModify":1728564939364,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4187758296730972","authorIdStr":"4187758296730972"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/358500956209384","repostId":"2474492713","repostType":2,"repost":{"id":"2474492713","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1728557104,"share":"https://www.laohu8.com/m/news/2474492713?lang=&edition=full","pubTime":"2024-10-10 18:45","market":"us","language":"zh","title":"辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2474492713","media":"Reuters","summary":" 路透10月10日 - 辉瑞 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌 患者的总生存期方面有明显改善，无论是否存在基因突变。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。 </p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-10 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。 </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4534":"瑞士信贷持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4588":"碎股","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4581":"高盛持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","PFE":"辉瑞","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4592":"伊斯兰概念","LU0058720904.USD":"联博国际健康护理基金A","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474492713","content_text":"((自动化翻译由路透提供，请见免责声明 )) 路透10月10日 - 辉瑞 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。 总生存期是指患者在确诊或开始治疗后的生存时间。mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。美国食品和药物管理局去年还批准了 (link) 阿斯利康公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。","news_type":1},"isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":354809377091696,"gmtCreate":1727632853162,"gmtModify":1727659988471,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4187758296730972","authorIdStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> ","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> ","text":"$特斯拉(TSLA)$","images":[{"img":"https://static.tigerbbs.com/39105e1c0d2e9a64ee0e9da20519a0c8","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354809377091696","isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":354157321466144,"gmtCreate":1727472307857,"gmtModify":1727473446624,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4187758296730972","authorIdStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSM\">$台积电(TSM)$ </a> 还能涨点不，亏了3个点了","listText":"<a href=\"https://laohu8.com/S/TSM\">$台积电(TSM)$ </a> 还能涨点不，亏了3个点了","text":"$台积电(TSM)$ 还能涨点不，亏了3个点了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354157321466144","isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350192179273744,"gmtCreate":1726524182516,"gmtModify":1726533279602,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4187758296730972","authorIdStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","listText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","text":"$英特尔(INTC)$","images":[{"img":"https://static.tigerbbs.com/ff10e42e4b49d1edb211098b04d85a27","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/350192179273744","isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":350115729961224,"gmtCreate":1726513133347,"gmtModify":1726533241047,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4187758296730972","authorIdStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","listText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","text":"$英特尔(INTC)$","images":[{"img":"https://static.tigerbbs.com/830a8f83b4da7af091e21d12373488d4","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/350115729961224","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":345901267095584,"gmtCreate":1725490768267,"gmtModify":1725495072715,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4187758296730972","authorIdStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","text":"$英伟达(NVDA)$","images":[{"img":"https://static.tigerbbs.com/266882ee40ec9f53a15c8e2455ed8714","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/345901267095584","isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":354809377091696,"gmtCreate":1727632853162,"gmtModify":1727659988471,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4187758296730972","idStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> ","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> ","text":"$特斯拉(TSLA)$","images":[{"img":"https://static.tigerbbs.com/39105e1c0d2e9a64ee0e9da20519a0c8","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354809377091696","isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":358500956209384,"gmtCreate":1728564937981,"gmtModify":1728564939364,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4187758296730972","idStr":"4187758296730972"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/358500956209384","repostId":"2474492713","repostType":2,"repost":{"id":"2474492713","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1728557104,"share":"https://www.laohu8.com/m/news/2474492713?lang=&edition=full","pubTime":"2024-10-10 18:45","market":"us","language":"zh","title":"辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2474492713","media":"Reuters","summary":" 路透10月10日 - 辉瑞 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌 患者的总生存期方面有明显改善，无论是否存在基因突变。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。 </p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-10 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。 </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4534":"瑞士信贷持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4588":"碎股","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4581":"高盛持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","PFE":"辉瑞","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4592":"伊斯兰概念","LU0058720904.USD":"联博国际健康护理基金A","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474492713","content_text":"((自动化翻译由路透提供，请见免责声明 )) 路透10月10日 - 辉瑞 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。 总生存期是指患者在确诊或开始治疗后的生存时间。mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。美国食品和药物管理局去年还批准了 (link) 阿斯利康公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。","news_type":1},"isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":354157321466144,"gmtCreate":1727472307857,"gmtModify":1727473446624,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4187758296730972","idStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSM\">$台积电(TSM)$ </a> 还能涨点不，亏了3个点了","listText":"<a href=\"https://laohu8.com/S/TSM\">$台积电(TSM)$ </a> 还能涨点不，亏了3个点了","text":"$台积电(TSM)$ 还能涨点不，亏了3个点了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354157321466144","isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350192179273744,"gmtCreate":1726524182516,"gmtModify":1726533279602,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4187758296730972","idStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","listText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","text":"$英特尔(INTC)$","images":[{"img":"https://static.tigerbbs.com/ff10e42e4b49d1edb211098b04d85a27","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/350192179273744","isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":350115729961224,"gmtCreate":1726513133347,"gmtModify":1726533241047,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4187758296730972","idStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","listText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> ","text":"$英特尔(INTC)$","images":[{"img":"https://static.tigerbbs.com/830a8f83b4da7af091e21d12373488d4","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/350115729961224","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":345901267095584,"gmtCreate":1725490768267,"gmtModify":1725495072715,"author":{"id":"4187758296730972","authorId":"4187758296730972","name":"Dowi","avatar":"https://static.tigerbbs.com/cc0052ada51082b856946953dc7870a2","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4187758296730972","idStr":"4187758296730972"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","text":"$英伟达(NVDA)$","images":[{"img":"https://static.tigerbbs.com/266882ee40ec9f53a15c8e2455ed8714","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/345901267095584","isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}
